PMID: 2123430Aug 1, 1990Paper

The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus

Diabetes Research and Clinical Practice
T M RoyM A Pfeifer

Abstract

Because some aldose reductase inhibitor studies have demonstrated clinical improvement in scored neurological signs and symptoms of diabetic neuropathy, a prospective study of the effect on cardiovascular performance of sorbinil 250 mg/day for 12 months was conducted on patients with diabetic autonomic neuropathy who were free of atherosclerotic coronary artery disease and/or cardiomyopathy. After 1 year of treatment, the study group (n = 14) demonstrated significant improvement in both the resting cardiac output (P = 0.02), and the maximal cardiac output (P = 0.03). This observation suggests that the use of an aldose reductase inhibitor may be useful in treating suboptimal cardiovascular performance in patients with diabetic cardiac autonomic neuropathy.

References

Jun 1, 1979·Diabetes·R S Clements
Apr 1, 1986·Metabolism: Clinical and Experimental·G B WillarsJ P Robinson
Oct 1, 1989·The American Journal of Medicine·T M RoyM A Pfeifer
Nov 15, 1985·The American Journal of Medicine·D A Greene, S A Lattimer
Aug 13, 1987·The New England Journal of Medicine·J HilstedH Galbo
Jul 1, 1986·The Journal of Clinical Endocrinology and Metabolism·B ZolaA I Vinik
Jan 1, 1967·Journal of Applied Physiology·K WassermanG G Burton
Jun 11, 1981·The New England Journal of Medicine·K K Hui, M E Conolly
Apr 1, 1982·The Journal of Clinical Investigation·B DaviesP Sever
May 1, 1982·Clinical and Experimental Pharmacology & Physiology·A J Man in 't Veld, M A Schalekamp
Jan 20, 1983·The New England Journal of Medicine·R G JudzewitschD Porte
Aug 1, 1984·Journal of the American College of Cardiology·R R MildenbergerP R McLaughlin
Aug 1, 1983·The American Journal of Medicine·M A PfeiferJ B Halter
Jul 1, 1964·Journal of Applied Physiology·A NAIMARKM B MCILROY
Apr 9, 1966·British Medical Journal·J A MoorhouseJ Doupe

❮ Previous
Next ❯

Citations

Apr 1, 1992·Diabetes/metabolism Reviews·D R Tomlinson
Sep 18, 1991·Molecular and Cellular Biochemistry·S W Schaffer
Apr 1, 1993·Clinical and Experimental Pharmacology & Physiology·R J Booth, W C Hodgson
Jan 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·H M Krans
Jan 2, 2007·Autonomic Neuroscience : Basic & Clinical·Miguel Debono, Elaine Cachia
Jul 8, 2008·Journal of the Peripheral Nervous System : JPNS·David R Tomlinson, Natalie J Gardiner
Oct 1, 1991·Diabetes Research and Clinical Practice·D ZieglerF A Gries
Dec 14, 2005·Pharmacology & Therapeutics·Hana FarhangkhoeeSubrata Chakrabarti
Feb 13, 2015·Antioxidants & Redox Signaling·Miguel A AonSonia Cortassa
Jan 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·V L BroadstoneM A Pfeifer
Aug 6, 2004·Endocrine Reviews·Zhi You FangThomas H Marwick
Oct 1, 1992·Metabolism: Clinical and Experimental·A KashiwagiY Saeki
Nov 15, 1997·Metabolism: Clinical and Experimental·S LalB S Szwergold

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.